RecruitingNot Applicable

Impact of Echocardiography on Management of Critically Ill Neonates

Egypt50 participantsStarted 2024-08-01

Plain-language summary

The goal of the study was to estimate the outcome (mortality and morbidity) among hemodynamically unstable neonates, as well as the time to return to hemodynamic stability following the use of ECHO in the management of hemodynamically unstable neonates.

Who can participate

Age range

2 Hours – 28 Days

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All neonates ( age 0 to 28 days) admitted to the NICU of Sohag University Hospital during the period of the study in whom manifestations of hemodynamic instability or critical illness were elected regardless of gestational age, weight, gender, or type of disease. Exclusion Criteria: * Failure to obtain informed consent . * Presence of congenital heart disease apart from PDA , PFO \& small ASD .

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Functional echocardiography ( ejection fraction using M mode echocardiography)

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval)

Functional echocardiography fraction shortening by M mode echocardiography

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval)

Assessment of ductus arteriosus ( diameter, shunt directionality ) by 2D and color doppler echocardiography

Timeframe: Repeat echocardiographic assessment 5 days after the first echo assessment

Assessment of pulmonary hypertension

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval) following proposed treatment of pulmonary hypertension

Assessment of LV cardiac index

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval)

Assessment of RV cardiac index

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval)

Trial details

NCT IDNCT06533787

SponsorSahar Abozkaly Mahmoud

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-08

Contact for this trial

Sahar Abuzakaly Mahmoud, MBBS

01145168107 sahar.abozakaly@med.sohag.edu.eg

View on ClinicalTrials.gov More Critical Illness trials

Who can participate

Age range

2 Hours – 28 Days

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Functional echocardiography ( ejection fraction using M mode echocardiography)

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval)

Functional echocardiography fraction shortening by M mode echocardiography

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval)

Assessment of ductus arteriosus ( diameter, shunt directionality ) by 2D and color doppler echocardiography

Timeframe: Repeat echocardiographic assessment 5 days after the first echo assessment

Assessment of pulmonary hypertension

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval) following proposed treatment of pulmonary hypertension

Assessment of LV cardiac index

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval)

Assessment of RV cardiac index

Timeframe: Repeat echocardiographic assessment on a daily basis ( 24 hours interval)